Sugi Predict

Sugi Predict / Compounds / SCHEMBL316084

SCHEMBL316084

SCHEMBL316084

CC(C)(C)OC(=O)N[C@@H](CSSC[C@H](NC(=O)OC(C)(C)C)C(=O)O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 11/20 0.57
▸ PPARG P37231 10/20 0.57
▸ PPARD Q03181 2/20 0.54
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ CTSS P25774 5/20 0.50
▸ CTSK P43235 5/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ ACE P12821 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2541324 1.00 PPARA (0.57) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL432222 1.00 PPARA (0.57) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL13489723 1.00 PPARA (0.57) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL5351802 1.00 PPARA (0.57) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL7423487 0.94 PPARA (0.55) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL22636123 0.94 CYP1A2 (0.55) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL22381014 0.94 PPARA (0.55) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL22636121 0.94 CYP1A2 (0.55) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL12660176 0.94 PPARA (0.52) PPARAPPARGPPARDCYP1A2CYP2C9
SCHEMBL16289560 0.94 PPARA (0.55) PPARAPPARGPPARDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118812628-A Mannosylated seryl cystatin dioleamine compound, and preparation method and application thereof 制能(北京)生物科技有限公司 2024-10-22 — — CN claimed
WO-2024104138-A1 N-TERMINAL FUNCTIONALIZATION-MODIFIED CYSTYL DIOLEYLAMINE COMPOUND, CHEMICAL SYNTHESIS METHOD THEREFOR, AND USE THEREOF 北京大学 2024-05-23 — — WO claimed
CN-115746088-A N-terminal functional modified cystadipamide compound and chemical synthesis method and application thereof 北京大学 2023-03-07 — — CN claimed
CN-112595788-B High performance liquid chromatography method for separating (R), (S) -1- (alpha-naphthyl) glycidyl ether 云南贝斯泰生物科技有限公司 2022-04-19 — — CN claimed
US-12486241-B2 Cystine diamide analogs for cystinuria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-12-02 — — US disclosed
US-20250282817-A1 COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME OREGON STATE UNIVERSITY (US) 2025-09-11 — — US disclosed
US-12391661-B2 Cystine diamide analogs for the prevention of cystine stone formation in cystinuria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-08-19 — — US disclosed
US-20250163091-A1 FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-05-22 — — US disclosed
CN-119409627-A Preparation method of Boc-Cys (S-Py) -OH 苏州天马医药集团天吉生物制药有限公司 2025-02-11 — — CN disclosed
CN-116199572-B Method for alpha-bromination of iron-catalyzed ketone 南京师范大学 2025-01-14 — — CN disclosed
CN-118948763-A Micelle capable of relieving neurotoxicity and preparation method and application thereof 陕西科技大学 2024-11-15 — — CN disclosed
CN-118812628-A Mannosylated seryl cystatin dioleamine compound, and preparation method and application thereof 制能(北京)生物科技有限公司 2024-10-22 — — CN disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 — — US disclosed
US-20020160515-A1 Formation of polyampholytes in the presence of a polyion Arrowhead Madison Inc. 2002-10-31 — — US disclosed
EP-1034163-A1 NEW CYSTEINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICALS CONTAINING THEM Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin (DE) 2000-09-13 — — EP disclosed
EP-0997147-A1 AMINO ACID DERIVATIVES Ono Pharmaceutical Co., Ltd. (JP) 2000-05-03 — — EP disclosed
EP-0764149-B1 NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME RHONE POULENC RORER SA (FR) 1999-01-20 — — EP disclosed
US-5861529-A ANTICANCER AGENTS RHONE-POULENC RORER S.A. (FR) 1999-01-19 — — US disclosed
WO-1998050351-A1 NEW CYSTEINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICALS CONTAINING THEM Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin (DE) 1998-11-12 — — WO disclosed
US-4913852-A Compounds obtained from the associative synthesis of sulfur-containing or sulfur-free amino acids with pregnane derivatives MILIONI CATHERINE (GR) 1990-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486241-B2 Cystine diamide analogs for cystinuria CTH, CBS, SLC7A11 PPARA 4222/4885PPARG 4586/4885PPARD 4010/4885
US-12391661-B2 Cystine diamide analogs for the prevention of cystine stone formation in cystinuria CTH, CBS, SLC6A12 PPARA 3988/4885PPARG 4450/4885PPARD 3862/4885
US-20250282817-A1 COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME GSR, TXN2, GLS PPARA 435/4885PPARG 184/4885PPARD 643/4885
US-20250163091-A1 FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM GALNT6, GALNT2, GALNT1 PPARA 4787/4885PPARG 4601/4885PPARD 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.